Utilizing a validated RNA signature to risk stratify developing fibrosis in transplant patients
Currently, histological analysis from biopsy of the kidney remains the primary method for assessing fibrosis; however, effectively managing fibrosis has long posed a significant challenge for transplant clinicians. Protega™ is reported as a risk score between 0 – 100 to inform the clinician of the patient’s risk of developing progressive fibrosis. The classification of low vs. high risk is based on associated increased histopathologic changes (i.e. interstitial fibrosis) between time points of surveillance or for-cause kidney biopsies.
Protega™ is an in vitro prognostic assay that analyzes multiple RNA biomarkers from peripheral blood post-kidney transplant. A clinically validated cutoff and risk score classifies kidney transplant recipients as either low or high risk for developing progressive fibrosis as per BANFF 2019 criteria in the kidney allograft.
Contact us for more information or to order Protega™
